

Advanced Imaging Digest


Gamma Knife Radiosurgery

Introduction

Stereotactic radiosurgery uses highly specialized equipment to focus beams of radiation only where they are needed to treat brain and spinal tumors, vascular lesions or neurologic conditions, such as trigeminal neuralgia, without damaging healthy brain tissue.

Radiosurgery differs from conventional radiation therapy in several respects. With standard external beam radiation therapy techniques, tumors and some of the surrounding normal tissues are treated to the same dose of radiation. The radiation dose is given in small increments over several weeks to allow normal adjacent tissues to recover from its effect, while tumor tissue is less likely to recover.

Ultimately, the brain can absorb a maximal dose of radiation beyond which no further treatment is advisable. There is increasing evidence that over long periods of time, high doses of radiation are harmful to a normally functioning brain. Radiosurgery treats only the abnormal tissue in a single session without significant radiation to the adjacent brain.




The Elekta Gamma Knife (GK) is a cutting-edge, non-invasive stereotactic radiosurgery instrument that doesn't use a scalpel or require an incision—in fact, it's not a knife at all. Instead, the GK uses 192-201 small cobalt sources of gamma rays arrayed in a hemisphere within a thickly shielded structure. A collimator aims the radiation emitted by these sources to a common focal point. This is analogous to focusing the radiant energy of the sun with a magnifying glass to a hot focus. Near the glass there is not much heat, but the energy is intense at the focal point. Optical lenses cannot focus gamma rays, rather individual beams are allowed to summate by overlapping at the focal point of the collimator,

achieving the same effect. The collimator allows the beam focus size to be adjusted from 4 to 18mm in size.

GK radiosurgery can be especially beneficial when a brain tumor is hard to reach with traditional neurosurgery or when a patient is not healthy enough to undergo traditional surgery. GK radiosurgery doesn't require an incision or general anesthesia. Most patients can resume their daily activity within a day or two, depending on their doctor's advice.

How Gamma Knife works




Leksell Gamma Knife


SUMMARY OF NEUROLOGICAL DISORDERS TREATABLE WITH LEKSELL GAMMA KNIFE

		Annual Incidence (per million)	% indicated for Gamma Knife treatment	Annual Gamma Knife cases (per million)
Vascular Malformations	Arteriovenous Malformations	8.9–13.4 ¹⁻³	70	6.2–9.4
	Cavernous Malformations	1.5–5.6 ⁴	15	0.2–0.84
	Dural Arteriovenous Fistulas	1.7 ⁵	50	0.85
Functional Disorders	Trigeminal Neuralgia	126–289 ⁶⁻⁷	50	63–144.5
	Essential Tremor	237 ⁸	50	118.5
	Parkinson's Tremor	200 ⁹	15	30
	Epilepsy	610 ¹⁰	5	30.5
Benign Tumors	Meningioma	86 ¹¹	50	43
	Pituitary Adenoma	40.1 ¹¹	15	6
	Vestibular Schwannoma	20 ¹¹	80	16
	Craniopharyngioma	1.3 ¹²	20	0.26
Malignant Tumors	Metastases	300–500 ¹³⁻¹⁴	90	270–450
	Glioblastoma Multiforme	32 ¹¹	20	6.4
	Anaplastic Astrocytoma	5.9 ¹¹	20	1.1
	Diffuse Astrocytoma	4.6 ¹¹	20	0.9
	Lymphoma	4.3 ¹¹	10	0.43
	Uveal Melanoma	5.1 ¹⁵	40	2.04
TOTAL				595–861

OVER 1.3 MILLION PATIENTS TREATED WITH LEKSELL GAMMA KNIFE THROUGH 2019 WORLDWIDE



INDICATIONS TREATED ANNUALLY WITH LEKSELL GAMMA KNIFE THROUGH 2019 WORLDWIDE



Open surgery versus Gamma Knife radiosurgery

The average 12-month cost of open surgery versus GK radiosurgery:

- Brain metastases: \$55,938 vs. \$23,069
- Acoustic neuroma: \$67,538 vs. \$37,840
- Arteriovenous malformations: \$78,332 vs. \$46,293

Patients typically are in and out of the hospital in one day for a single treatment and back to their normal routines quickly. GK radiosurgery may be used in place of or in addition to traditional brain surgery or whole brain radiation for the treatment of complex brain conditions.

Despite the significant advantages of GK radiosurgery, appropriate selection of eligible patients based on published data will result in preventing overutilization of this procedure.

About the author

Noushin Izadifar Hart, senior physician clinical reviewer, radiation oncology, Magellan Healthcare

Dr. Hart completed her residency in radiation oncology and a year of research at Washington University. She is board certified by the American Board of Radiology. She was a clinical assistant professor in radiation oncology at Loyola University School of Medicine in Chicago before moving to Houston where she has been in private practice for the past eighteen years. With six years of prior experience in utilization review, Dr. Hart has been a physician clinical reviewer, at Magellan Rx since December 2019. In November of 2021, she became a senior physician clinical Reviewer in radiation oncology. She is passionate about evidence-based healthcare delivery and looks forward to expanding her role at Magellan Rx.



References:

Aoyama H, Tago M, et al. Stereotactic Radiosurgery with or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial. *JAMA oncology*. 2015;1(4):457-64.

Berman MF, Sciacca RR, Pile-Spellman J, et al. The epidemiology of brain arteriovenous malformations. *Neurosurgery*. 2000;47(2):389-396; discussion 397.

Brown PD, Jaeckle K, et al. Effect of Radiosurgery Alone vs Radiosurgery with Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. *JAMA*. 2016;316(4):401-409.

Cho A, Untersteiner H, et al. Gamma Knife Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy or Targeted Therapy. *Cancers (Basel)*. 2020 Dec 7;12(12). pii: cancers12123668.

Churilla TM, Ballman KV, et al. Stereotactic Radiosurgery with or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial. *International journal of radiation oncology, biology, physics*. 2017;99(5):1173-1178.

Churilla TM, Chowdhury IH, et al. Comparison of Local Control of Brain Metastases with Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial. *JAMA oncology*. 2019;5(2):243-247.

Churilla TM, Handorf E, et al. Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary

analysis of EORTC 22952-26001. *Annals of oncology: official journal of the European Society for Medical Oncology*. 2017;28(10):2588-2594.

Cifarelli CP, Vargo JA, et al. Role of Gamma Knife Radiosurgery in Small Cell Lung Cancer: A Multinstitutional Retrospective Study of the International Radiosurgery Research Foundation (IRRF). *Neurosurgery*. 2020 Sep 15;87(4):664-671.

Fiest KM, Sauro KM, Wiebe S, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. *Neurology*. 2017;88(3):296-303.

Ghobrial GM, Marchan E, Nair AK, et al. Dural arteriovenous fistulas: a review of the literature and a presentation of a single institution's experience. *World Neurosurg*. 2013;80(1-2):94-102.

Goldstein HE, Solomon RA. Epidemiology of cavernous malformations. *Handb Clin Neurol*. 2017; 143:241-247.

Ito D, Aoyagi K, et al. Comparison of two-stage Gamma Knife radiosurgery outcomes for large brain metastases among primary cancers. *Journal of neuro-oncology*. 2020;147(1):237-246.

Kennedy WR, DeWees TA, et al. Internal dose escalation associated with increased local control for melanoma brain metastases treated with stereotactic radiosurgery. *J Neurosurg*. 2020 Dec 11:1-7.

Kim H, Su H, Weinsheimer S, et al. Brain arteriovenous malformation pathogenesis: a response-to-injury paradigm. *Acta Neurochir Suppl*. 2011; 111:83-92.

Kubler J, Wester-Ebbinghaus M, et al. Postoperative stereotactic radiosurgery and hypofractionated radiotherapy for brain metastases using Gamma Knife and CyberKnife: a dual-center analysis. *Journal of neurosurgical sciences*. 2020.

Laakso A, Hernesniemi J. Arteriovenous malformations: epidemiology and clinical presentation. *Neurosurg Clin N Am*. 2012;23(1):1-6.

Lee MH, Cho KR, et al. Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis: The Role of Gamma Knife Radiosurgery. *J Korean Neurosurg Soc*. 2020 Dec 4. pii: jkns.2020.0135.

Lim SH, Lee JY, et al. A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. *Annals of oncology: official journal of the European Society for Medical Oncology*. 2015;26(4):762-768.

Marras, C., Beck, J. C., Bower, J. H., Roberts, E., Ritz, B., Ross, G. W., Abbott, R. D., Savica, R., Van Den Eeden, S. K., Willis, A. W., Tanner, CM, on behalf of the Parkinson's Foundation P4 Group. Prevalence of Parkinson's disease across North America. *Npj Parkinson's Disease*. 4(1), 1–7.

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Central Nervous System Cancers, Version 2.2021 – September 8, 2021.

Ogino A, Hirai T, Serizawa T, et al. Gamma Knife Surgery for Brain Metastases from Uterine Malignant Tumor. *World Neurosurg.* 2020 Jul;139: e363-e372.

Reddy GD, Viswanathan A. Trigeminal and glossopharyngeal neuralgia. *Neurol Clin.* 2014;32(2):539-552.

Redmond KJ, Gui C, Benedict S, et al. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases. *Int J Radiat Oncol Biol Phys.* 2020 Dec 31. pii: S0360-3016(20)34451-5.

Robin TP, Rusthoven CG, et al. Radiosurgery for small-cell lung cancer brain metastases: a review. *J Thorac Dis.* 2020 Oct;12(10):6234-6239.

Stenman M, Benmakhlouf H, et al. Metastatic renal cell carcinoma to the brain: optimizing patient selection for gamma knife radiosurgery. *Acta Neurochir (Wien).* 2020 Sep 9. pii: 10.1007/s00701-020-04537-w.

Verhaak E, Schimmel WCM, et al. Health-related quality of life after Gamma Knife radiosurgery in patients with 1-10 brain metastases. *J Cancer Res Clin Oncol.* 2020 Oct 6. pii: 10.1007/s00432-020-03400-w.

Wilson TG, Robinson T, et al. Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery. *Clin Oncol (R Coll Radiol).* 2020 Jun;32(6):390-396.

Yamamoto M, Serizawa T, et al. Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years, or older vs 65-74 years. *Lung Cancer.* 2020 Aug 18; 149:103-112.

Zakrzewska JM, McMillan R. Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. *Postgrad Med J.* 2011;87(1028):410-416.

Zesiewicz TA, Chari A, Jahan I, Miller AM, et al. Overview of essential tremor. *Neuropsychiatr Dis Treat.* 2010; 6:401-408.